Increasing Medical Marijuana and Cannabidiol Research

Executive Order 14370 is an executive action signed by President (name not specified in text) that directs Federal officials to increase research and change rules for medical marijuana and hemp-derived cannabidiol (CBD) products. The Attorney General must finish the rulemaking to reschedule marijuana to Schedule III (changing a drug's classification under the Controlled Substances Act) as quickly as federal law allows (Sec. 2(a)). The Assistant to the President must work with Congress to update the statutory definition and create a regulatory framework for hemp-derived cannabinoid products, while HHS, the FDA, CMS, and NIH must develop research methods using real-world evidence (Sec. 2(b)). This matters because it aims to give patients and doctors better information, affect product rules, and change how research and access work for Americans.